Inequities in the Geographic Accessibility of COVID-19 Biomedical Therapeutic Trials in the United States

KEY WORDS: Coronavirus disease 2019 (COVID-19); Clinical trials; Rural health; Health disparities; Access to care.

J Gen Intern Med 36(11):3650–3
DOI: 10.1007/s11606-021-07081-0
© The Author(s) 2021

INTRODUCTION

Coronavirus disease 2019 (COVID-19) has disproportionately impacted marginalized communities across the United States (US). However, racial/ethnic minority and elderly populations experiencing the highest COVID-19 incidence, hospitalization, and mortality rates have not been equitably enrolled in clinical trials investigating potential COVID-19 therapeutics.

We descriptively evaluated the geographic proximity of demographic subpopulations to COVID-19 biomedical therapeutic trial sites. We hypothesized that trial sites would be more accessible to urban populations and subgroups who more often live in urban areas (racial/ethnic minority and younger populations).

METHODS

For this cross-sectional analysis, we queried ClinicalTrials.gov for trials with keywords “coronavirus disease 2019,” “COVID-19,” and “SARS-CoV-2” and start dates between January 20th and September 20th, 2020. To identify biomedical therapeutic trials, two authors excluded observational, suspended, terminated, withdrawn, and non-therapeutic trials.

We geocoded trial site addresses using Google Places API. We calculated drive times from the center of population for each census tract to the ten geographically closest sites and selected the site with the shortest time. We stratified rural and urban tracts using 2010 USDA ERS Rural-Urban Commuting Area codes. We calculated the proportion of each demographic subgroup residing within x minutes of the nearest trial site by weighting each tract by population demographics (age, race, ethnicity) from the 2015–2019 US Census American Community Survey (ACS). We calculated median drive times with 95% confidence intervals by bootstrap.

We performed statistical analyses using RStudio v1.3.1073 (R Foundation for Statistical Computing), and plotted maps using ArcMap v10.7.1. The University of Virginia Institutional Review Board deemed this study exempt.

RESULTS

We identified 310 biomedical therapeutic trials with 2095 trial sites, including 246 (79.4%) randomized trials. Median trial enrollment was 117 (IQR 335). Most trials included all genders (307 [99.0%]) and adults older than 18 years (285 [91.9%]). One hundred seventy-two (55.5%) were single-center studies (range 1–117 sites). The most studied interventions included convalescent plasma (37 [11.9%]), hydroxychloroquine (25 [8.1%]), and remdesivir (11 [3.5%]).

Trial sites were clustered near metropolitan centers (Figure 1A), with corresponding shorter drive times near urban areas (Figure 1B). Overall, 31.3% of the US population and 76.0% of the rural population lived > 60 min from the nearest trial site. 33.7% of elderly (age 65+), 56.3% of American Indian/Alaskan Native (AIAN), 32.8% of White, 18.5% of Hispanic, and 10.7% of Black people lived > 60 min from the nearest site.

Rural census tracts (median 85.2 mins [95% CI: 83.9–86.4]) had significantly longer drive times than urban tracts (18.7 [18.4–18.9]) for all demographic groups (Figure 2). After stratifying by rurality, only median drive times for AIAN people were still significantly longer than drive times for the overall population in both urban (AIAN: 20.8 [19.9–21.9]; overall: 18.7 [18.4–18.9]) and rural (104.9 [95.1–114.3]; 85.2 [83.9–87.8]) tracts.

DISCUSSION

Similar to the geographic inaccessibility of clinical trials for other diseases, the opportunity to enroll in biomedical therapeutic trials throughout the first 8 months of
the COVID-19 pandemic was not equitably available across the US. Nearly one-third of the overall US population, over one-half of AIAN people, and over three-fourth of the rural population lived more than an hour from the nearest trial site. Rural-urban differences in trial distribution explain longer overall drive times for White and elderly populations, since these groups disproportionately resided in rural census tracts. However, the AIAN population faced longer drive times even when accounting for rurality, suggesting they are uniquely geographically isolated from novel therapeutics.

Non-Hispanic and White individuals were well-represented in COVID-19 trials despite rural trial inaccessibility and lower hospitalization rates. Furthermore, the underrepresentation of Black and Hispanic populations in COVID-19 therapeutic trials is especially striking given their relative geographic proximity to trial sites and disproportionate hospitalization rates, both of which suggest greater opportunity for recruitment. Factors unexplored herein—including racism, mistrust, language barriers, and the persistent segregation of well-resourced hospitals—should be investigated further as potential mediators of decreased trial enrollment.

Our study has limitations, including that our use of tract centers of population assumes demographic groups are not clustered within tracts. We also did not account for vehicle access or reliance on public transportation. Thus, our tract-level analyses may misestimate travel times for vehicle-less and demographically segregated urban populations.
Beyond the COVID-19 era, innovations like decentralized, Internet-based clinical trials may help mitigate geographic inequities. However, it remains clear that geographic accessibility alone may not improve racial/ethnic representation in the absence of additional structural interventions.

Rohan Khazanchi, MPH
Samuel D. Powers, MA
Elizabeth T. Rogawski McQuade, PhD
Kathleen A. McManus, MD, MSCR

1College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
2University of Minnesota School of Public Health, Minneapolis, MN, USA
3Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia, PO Box 801379, Charlottesville, VA 22908, USA
4Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA
5Global Infectious Disease Institute, University of Virginia, Charlottesville, VA, USA

Corresponding Author: Kathleen A. McManus, MD, MSCR; Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia, PO Box 801379, Charlottesville, VA 22908, USA (e-mail: km8jr@virginia.edu).

Funding: This work was supported by the University of Virginia Global Infectious Disease Institute.

Data Availability: The data analyzed for this study are publicly available from http://clinicaltrials.gov/

Declarations:

Conflict of Interest: Dr. McManus reported receiving investigator-initiated research funding from Gilead Sciences, Inc.; owning stock in Gilead Sciences, Inc., and receiving grants from the National Institute of Allergy and Infectious Diseases (NIAID). All authors submitted ICMJE Conflict of Interest forms, and no other authors reported relevant disclosures.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
REFERENCES

1. Khazanchi R, Better ER, Gondi S, Beckman AL, Bilinski A, Ganguli I. County-Level Association of Social Vulnerability with COVID-19 Cases and Deaths in the USA. J Gen Intern Med. 2020;35(9):2784-2787. doi: https://doi.org/10.1007/s11606-020-05882-3

2. Chastain DB, Osae SP, Henao-Martinez AF, Franco-Paredes C, Chastain JS, Young HN. Racial Disproportionality in Covid Clinical Trials. N Engl J Med. 2020;383(9):e59. doi: https://doi.org/10.1056/NEJMp2021971

3. Helfand BKI, Webb M, Gartaganis SL, Fuller L, Kwon C-S, Inouye SK. The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019—Missing the Target. JAMA Intern Med. 2020;180(11):1546-1549. doi: https://doi.org/10.1001/jamainternmed.2020.5084

4. Galsky MD, Stensland KD, McBride RB, et al. Geographic Accessibility to Clinical Trials for Advanced Cancer in the United States. JAMA Intern Med. 2015;175(2):293. doi: https://doi.org/10.1001/jamainternmed.2014.6300

5. Warren RC, Farrow L, Hodge DA, Truog RD. Trustworthiness before Trust — Covid-19 Vaccine Trials and the Black Community. N Engl J Med. 2020;383(22):e121. doi: https://doi.org/10.1056/NEJMp2030033

6. Gaba P, Bhatt DL. The COVID-19 pandemic: a catalyst to improve clinical trials. Nat Rev Cardiol. 2020;17(11):673-675. doi: https://doi.org/10.1038/s41569-020-00439-7

**Publisher's Note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.